JNJ

234.31

+0.56%↑

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

RDY

13.99

+1.3%↑

NEOG

10.53

+2.53%↑

JNJ

234.31

+0.56%↑

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

RDY

13.99

+1.3%↑

NEOG

10.53

+2.53%↑

JNJ

234.31

+0.56%↑

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

RDY

13.99

+1.3%↑

NEOG

10.53

+2.53%↑

JNJ

234.31

+0.56%↑

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

RDY

13.99

+1.3%↑

NEOG

10.53

+2.53%↑

JNJ

234.31

+0.56%↑

ISRG

478.08

-0.13%↓

ABT

108.15

-0.74%↓

RDY

13.99

+1.3%↑

NEOG

10.53

+2.53%↑

Search

United Therapeutics Corp

Gesloten

SectorGezondheidszorg

482.4 0.93

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

472.51

Max

485.42

Belangrijke statistieken

By Trading Economics

Inkomsten

29M

339M

Verkoop

900K

800M

K/W

Sectorgemiddelde

18.006

84.243

Winstmarge

42.364

Werknemers

1,305

EBITDA

26M

463M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+16.88% upside

Dividenden

By Dow Jones

Volgende Winsten

25 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.7B

21B

Vorige openingsprijs

481.47

Vorige sluitingsprijs

482.4

Nieuwssentiment

By Acuity

18%

82%

32 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

United Therapeutics Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 feb 2026, 23:11 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 feb 2026, 23:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 feb 2026, 23:50 UTC

Marktinformatie

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 feb 2026, 23:42 UTC

Marktinformatie

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 feb 2026, 23:41 UTC

Acquisities, Fusies, Overnames

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 feb 2026, 23:38 UTC

Winsten

AMD Sales Climb on Help From Data-Center Business -- Update

3 feb 2026, 23:29 UTC

Acquisities, Fusies, Overnames

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 feb 2026, 23:27 UTC

Acquisities, Fusies, Overnames

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 feb 2026, 23:25 UTC

Acquisities, Fusies, Overnames

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 feb 2026, 23:23 UTC

Acquisities, Fusies, Overnames

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 feb 2026, 23:22 UTC

Acquisities, Fusies, Overnames

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 feb 2026, 23:19 UTC

Marktinformatie

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 feb 2026, 23:19 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 feb 2026, 22:56 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 feb 2026, 22:40 UTC

Winsten

Amdocs Extends Collaboration With T-Mobile

3 feb 2026, 22:39 UTC

Winsten

Amdocs 1Q Adj EPS $1.81

3 feb 2026, 22:39 UTC

Winsten

Amdocs 1Q Rev $1.16B

3 feb 2026, 22:39 UTC

Winsten

Amdocs 1Q EPS $1.45 >

3 feb 2026, 22:38 UTC

Winsten

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 feb 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 feb 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 feb 2026, 22:14 UTC

Winsten

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 feb 2026, 22:13 UTC

Winsten

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 feb 2026, 22:12 UTC

Winsten

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 feb 2026, 22:10 UTC

Winsten

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 feb 2026, 22:10 UTC

Winsten

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 feb 2026, 22:10 UTC

Marktinformatie

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 feb 2026, 22:10 UTC

Winsten

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 feb 2026, 22:09 UTC

Winsten

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 feb 2026, 22:09 UTC

Winsten

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Peer Vergelijking

Prijswijziging

United Therapeutics Corp Prognose

Koersdoel

By TipRanks

16.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 555.2 USD  16.88%

Hoogste 645 USD

Laagste 423 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor United Therapeutics Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

4

Buy

2

Hold

0

Sell

Technische score

By Trading Central

292.345 / 309.245Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

32 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
help-icon Live chat